MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma

Bibliographic Details
Title: MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma
Authors: Salvatore Raieli, Daniele Di Renzo, Silvia Lampis, Camilla Amadesi, Luca Montemurro, Andrea Pession, Patrizia Hrelia, Matthias Fischer, Roberto Tonelli
Source: Frontiers in Oncology, Vol 11 (2021)
Publisher Information: Frontiers Media S.A., 2021.
Publication Year: 2021
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: MYCN, immune system, neuroblastoma, immune signature, immune network, anti-MYCN antigene PNA, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: A wide range of malignancies presents MYCN amplification (MNA) or dysregulation. MYCN is associated with poor prognosis and its over-expression leads to several dysregulations including metabolic reprogramming, mitochondria alteration, and cancer stem cell phenotype. Some hints suggest that MYCN overexpression leads to cancer immune-escape. However, this relationship presents various open questions. Our work investigated in details the relationship of MYCN with the immune system, finding a correlated immune-suppressive phenotype in neuroblastoma (NB) and different cancers where MYCN is up-regulated. We found a downregulated Th1-lymphocytes/M1-Macrophages axis and upregulated Th2-lymphocytes/M2-macrophages in MNA NB patients. Moreover, we unveiled a complex immune network orchestrated by N-Myc and we identified 16 genes modules associated to MNA NB. We also identified a MYCN-associated immune signature that has a prognostic value in NB and recapitulates clinical features. Our signature also discriminates patients with poor survival in non-MNA NB patients where MYCN expression is not discriminative. Finally, we showed that targeted inhibition of MYCN by BGA002 (anti-MYCN antigene PNA) is able to restore NK sensibility in MYCN-expressing NB cells. Overall, our study unveils a MYCN-driven immune network in NB and shows a therapeutic option to restore sensibility to immune cells.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.625207/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2021.625207
Access URL: https://doaj.org/article/bad6d4a7273842c689a925b87929773e
Accession Number: edsdoj.bad6d4a7273842c689a925b87929773e
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2021.625207
Published in:Frontiers in Oncology
Language:English